Related Experiment Videos

Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients

K A Boki1, U Dafni, G A Karpouzas

  • 1Department of Pathophysiology, School of Medicine, National University of Athens, Greece.

Insights

This study compared Wegener

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Necrotizing vasculitis encompasses several distinct conditions with varying clinical presentations and outcomes.
  • Understanding the differences and similarities in clinical expression, treatment response, and immunogenetics is crucial for effective patient management.

Purpose of the Study:

  • To evaluate the clinical spectrum and outcomes of necrotizing vasculitis.
  • To assess the response to various therapeutic approaches based on major disease events.
  • To investigate the immunogenetic background of patients diagnosed with different types of vasculitis.

Main Methods:

  • Retrospective study of 66 Greek patients diagnosed with vasculitis according to ACR criteria.
  • Classification into Wegener's granulomatosis (WG), polyarteritis nodosa (PAN), and Churg-Strauss syndrome (CSS).
  • Analysis of clinical manifestations, demographic characteristics, serological markers (c-ANCA, HBsAg), HLA antigens, and treatment responses.

Main Results:

  • WG and PAN patients had similar demographics; PAN more frequently involved skin, GI tract, and peripheral nerves, while WG affected lungs, upper respiratory tract, kidneys, and ears.
  • Muscle weakness was exclusive to PAN, asthma to CSS. c-ANCA was characteristic of WG, and HBsAg was found in 22% of PAN patients.
  • No significant difference in the first major event between PAN and WG. Cyclophosphamide route impacted WG outcomes (P=0.006). WG showed increased DR1 frequency, PAN/CSS lacked DR3.

Conclusions:

  • Despite differing immunogenetic backgrounds and clinical expressions, patients with WG and PAN exhibit similar treatment responses, disease evolution, and survival rates.
  • Specific clinical features and serological markers aid in differentiating WG, PAN, and CSS.
  • The route of cyclophosphamide administration may influence outcomes in WG patients.

Related Concept Videos